Sotalol
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
- Sotalol
- Sotalol: From Antiarrhythmic Therapy to Sick Sinus Syndrome 2, Autosomal Dominant (Signal Flagged as Likely False Positive)
Using no external skill here — this is a direct content-generation task fully specified by the provided report template; I’ll produce the report against the given Evidence Pack.
Sotalol: From Antiarrhythmic Therapy to Sick Sinus Syndrome 2, Autosomal Dominant (Signal Flagged as Likely False Positive)
One-Sentence Summary
Sotalol is an antiarrhythmic (beta-blocking, potassium-channel-blocking) agent used internationally for atrial fibrillation and ventricular arrhythmias; no UK marketing authorisation is on file for this drug in this dataset. The TxGNN model’s top-ranked prediction — Sick Sinus Syndrome 2, Autosomal Dominant — is not supported by any clinical trial or literature evidence and is mechanistically implausible as a treatment target: Sotalol’s sinus-node-suppressing action would be expected to worsen, not treat, this condition. Across all seven candidates in this multi-indication screen, none currently meet the bar for a “Go” decision.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally licensed in the UK (no marketing authorisation on file); evidence in this pack indicates international use as an antiarrhythmic for atrial fibrillation and ventricular arrhythmias |
| Predicted New Indication (top-ranked) | Sick Sinus Syndrome 2, Autosomal Dominant |
| TxGNN Prediction Score | 99.76% |
| Evidence Level | L5 (model prediction only, no clinical trials or literature) |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed structured mechanism-of-action data is not available for this record (original_moa: [Data Gap]). However, evidence embedded in this pack’s literature abstracts indicates Sotalol is a non-selective beta-adrenergic blocker with Class III antiarrhythmic activity (IKr/potassium-channel blockade), consistent with its established international use for rhythm control in atrial fibrillation and management of ventricular arrhythmias, including in adults with congenital heart disease.
For the top-ranked prediction, the relationship between Sotalol’s known pharmacology and Sick Sinus Syndrome runs in the wrong direction. Beta-blockade and IKr-mediated repolarisation prolongation both suppress sinoatrial node automaticity and conduction; in a patient with sick sinus syndrome, this would be expected to aggravate bradycardia or precipitate sinus arrest rather than treat the condition. Sick sinus syndrome is typically listed as a caution or contraindication for beta-blockers and Class III antiarrhythmics in product literature, not an indication.
This suggests the very high TxGNN score reflects a structural artefact of the knowledge graph — Sotalol shares graph neighbours (sinus node, cardiac conduction pathway) with sick sinus syndrome because of a safety relationship, which the model appears to have encoded as a therapeutic one. No clinical trials or publications support treating sick sinus syndrome with Sotalol, and none should be sought on this basis; this is a signal for safety review, not repurposing.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Other Predicted Indications Screened
This evidence pack scored seven candidate indications for Sotalol. For completeness and to avoid over-weighting the (likely erroneous) top score, all are summarised below.
| Rank | Predicted Indication | TxGNN Score | Evidence Level | Recommendation | Note |
|---|---|---|---|---|---|
| 1 | Sick sinus syndrome 2, autosomal dominant | 99.76% | L5 | Hold | Mechanistically a contraindication signal, not a treatment signal — see above |
| 2 | Wildervanck syndrome | 99.65% | L5 | Hold | Congenital skeletal/otic syndrome; no mechanistic link to cardiac electrophysiology; likely graph noise |
| 3 | Sarcoglycanopathy (limb-girdle muscular dystrophy) | 99.64% | L5 | Research Question | Plausible only indirectly, via management of associated cardiomyopathy/arrhythmia (as with Duchenne/Becker MD); no trials or literature yet identified |
| 4 | Stroke disorder | 99.44% | L3 | Research Question | Best-evidenced candidate, but represents an extension of the existing AF-rhythm-control indication rather than a novel mechanism; identified trials mostly test ablation or other antiarrhythmics, not Sotalol specifically against stroke outcomes (NCT00007605, NCT00911508) |
| 5 | Manic bipolar affective disorder | 99.43% | L4 | Hold | Literature concerns a QT-prolongation drug–drug interaction risk with antipsychotics (e.g., risperidone) and a bradycardia case report during lithium co-therapy — these are safety signals, not efficacy evidence for mania |
| 6 | Macrocephaly, dysmorphic facies, and psychomotor retardation | 99.42% | L5 | Hold | Congenital neurodevelopmental syndrome; no mechanistic plausibility; no evidence |
| 7 | Obsolete susceptibility to ischaemic stroke | 99.23% | L5 | Hold | Duplicate/obsolete ontology term overlapping with #4; should be merged rather than pursued independently |
UK Market Information
Sotalol currently holds no marketing authorisation on file in this dataset (total_licenses: 0, market status: Not marketed). No product entries, dosage forms, or licensed indications are available to summarise.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: This dataset flags UK-specific SmPC warnings/contraindications as a blocking data gap (DG001) — this must be resolved before any safety assessment (S1) can proceed for this drug, regardless of which candidate indication is pursued.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (sick sinus syndrome) is not a genuine repurposing opportunity — it is best read as a mechanistic contraindication signal misclassified by the knowledge graph, with zero supporting trials or literature. Across the full set of seven predictions, none currently meet the evidence bar for “Go”; the most credible candidate (stroke-risk reduction) is an incremental extension of Sotalol’s existing antiarrhythmic use rather than a novel indication, and is only supported at L3 (indirect trial/literature evidence, no Sotalol-specific stroke-outcome trial).
To proceed, the following is needed:
- Resolve blocking data gap DG001: obtain UK/EU SmPC warnings and contraindications for Sotalol before any safety screening can begin
- Resolve DG002: confirm original mechanism of action and licensed indication(s) via DrugBank or an equivalent authoritative source
- Confirm current UK marketing/licensing status, since this record shows zero authorisations
- If pursuing the stroke-risk-reduction angle (rank 4): identify or commission a trial with Sotalol as the specific intervention and stroke/thromboembolism as a primary or secondary endpoint
- If pursuing the sarcoglycanopathy angle (rank 3): seek preclinical or observational data on antiarrhythmic management of cardiomyopathy in this specific muscular dystrophy population
- No further action recommended on ranks 1, 2, 5, 6, or 7 without new evidence, given absent or contraindicated mechanistic rationale
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.